Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.
The classification of Biosimilar Monoclonal Antibodies includes Infliximab, Rituximab, Trastuzumab, Adalimumab and Other, and the sales proportion of Infliximab in 2017 is about 36.5%.
Biosimilar Monoclonal Antibodies is widely used for Oncology, Autoimmune Disease and Others. The most proportion of Biosimilar Monoclonal Antibodies is sales in Autoimmune Disease, and the consumption proportion is about 85.6% in 2017.
According to this study, over the next five years the Biosimilar Monoclonal Antibodies market will register a 27.5% CAGR in terms of revenue, the global market size will reach US$ 9240 million by 2024, from US$ 2750 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Biosimilar Monoclonal Antibodies business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar Monoclonal Antibodies market by product type, application, key manufacturers and key regions and countries.
This study considers the Biosimilar Monoclonal Antibodies value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
- Infliximab
- Rituximab
- Trastuzumab
- Adalimumab
- Other
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
- Oncology
- Autoimmune Disease
- Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Spain
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
- Celltrion
- Pfizer (Hospira)
- 3SBIO
- Novartis (Sandoz)
- Dr Reddy?s
- Celgen Biopharma
- Cadila Healthcare
- Hisun Pharma
- Torrent Pharmaceuticals
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
Table of content
2019-2024 Global Biosimilar Monoclonal Antibodies Consumption Market Report
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Biosimilar Monoclonal Antibodies Consumption 2014-2024
2.1.2 Biosimilar Monoclonal Antibodies Consumption CAGR by Region
2.2 Biosimilar Monoclonal Antibodies Segment by Type
2.2.1 Infliximab
2.2.2 Rituximab
2.2.3 Trastuzumab
2.2.4 Adalimumab
2.2.5 Other
2.3 Biosimilar Monoclonal Antibodies Consumption by Type
2.3.1 Global Biosimilar Monoclonal Antibodies Consumption Market Share by Type (2014-2019)
2.3.2 Global Biosimilar Monoclonal Antibodies Revenue and Market Share by Type (2014-2019)
2.3.3 Global Biosimilar Monoclonal Antibodies Sale Price by Type (2014-2019)
2.4 Biosimilar Monoclonal Antibodies Segment by Application
2.4.1 Oncology
2.4.2 Autoimmune Disease
2.4.3 Other
2.5 Biosimilar Monoclonal Antibodies Consumption by Application
2.5.1 Global Biosimilar Monoclonal Antibodies Consumption Market Share by Application (2014-2019)
2.5.2 Global Biosimilar Monoclonal Antibodies Value and Market Share by Application (2014-2019)
2.5.3 Global Biosimilar Mono
CONTACT US:
276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170 / +91 8087042414
Email: [email protected]
Follow Us On linkedin :- https://www.linkedin.com/company/grand-research-store/
It includes the size, share, growth, trends, key players, segments and regional analysis in detail during the study year 2020-2027.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the monoclonal antibodies market include Roche, Eli Lilly, Genentech, Pfizer, Biogen Idec.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Monoclonal Antibodies Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/monoclonal-antibodies-market/download-sampleMarket DynamicsProduction of monoclonal antibodies is an old practice in laboratory research.
The continued interest in antibody product development is driven by the rapid advancement and understanding of disease at a molecular level.
MAbs are increasingly used for applications such as research and diagnosis, therapeutic tools in cancer and immunological disorders, and pharmacy, thus generating a great demand in the industry.
Currently, MAbs account for one-third of all the new treatments for leukaemia, arthritis, breast cancer, and transplant, their role in disease prediction and detection offers promise.
